Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) hit a new 52-week low during trading on Friday . The company traded as low as C$0.66 and last traded at C$0.67, with a volume of 125156 shares changing hands. The stock had previously closed at C$0.69.
Oncolytics Biotech Price Performance
The stock has a 50 day moving average of C$0.79 and a two-hundred day moving average of C$1.08. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The firm has a market capitalization of C$50.10 million, a P/E ratio of -1.81 and a beta of 1.35.
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Stories
- Five stocks we like better than Oncolytics Biotech
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Top 4 ETFs for China Exposure After Tariff Relief
- How to Use the MarketBeat Dividend Calculator
- Build a Complete Bond Portfolio With These 4 ETFs
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- MarketBeat Week in Review – 05/12 – 05/16
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
